GSK Invests $272 Million in New Vaccine Manufacturing Unit for Production of Shingles and RSV Vaccines

GlaxoSmithKline (GSK) has been pumping large sums of cash into expanding its vaccine manufacturing operations and today, it announced an investment of €250 ($272 million) into building a new unit for freeze-drying vaccines at its Wavre campus in Belgium.